Jessica Boklan, MD
Research Director, Center for Cancer and Blood Disorders; Director, Early Drug Development Program; Co-Director, Leukemia Program
Dr. Boklan serves as the Director of Clinical Research for the Center for Cancer and Blood Disorders. She also serves as Director of the Early Drug Development Program, Principal Investigator for the Children’s Oncology Group (COG) as well as Principal Investigator for the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC). She works with multiple national and international collaborators, evaluating the effects of new molecularly-targeted agents on cancer cells. Dr. Boklan is active in the development of clinical trials utilizing novel therapeutics in pediatric patients who do not respond to currently available standard cancer treatments. Dr. Boklan is especially interested in finding better treatments for leukemias. Dr. Boklan serves as the Co-Director of the Center’s Leukemia Program and sub-specializes in caring for patients with myeloid leukemias. Dr. Boklan’s other main clinical interest is in aplastic anemia and bone marrow failure syndromes. She serves as Principal Investigator for the North American Pediatric Aplastic Anemia Consortium (NAPAAC).
Hematology & Oncology
BA, Biochemical Sciences (Cum Laude), Harvard University- Cambridge, MA
MD, New York University- New York, NY
Pediatric Residency, Children’s Hospital of Philadelphia- PA
Pediatric Hematology/Oncology Fellowship, Memorial Sloan-Kettering Cancer Center, New York Hospital- New York, NY
- A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors. Gore L, Trippett TM, Katzenstein HM, Boklan J, Narendran A, Smith A, Macy ME, Rolla K; Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), Narashimhan N, Squillace RM, Turner CD, Haluska FG, Nieder M. Clinical Cancer Research. 19:3649-58, 2013.
- A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendren A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L; Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC). Pediatric Blood and Cancer. 60:230-6, 2013.
- Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ. Pediatric Blood and Cancer. 59:1252-8, 2012.
- Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A. OncoTargets and Therapy. 4:149-68, 2011.
- Phase I and pharmacokinetic study of Cetuximab and Irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, Hunger SP, Boklan J, Smith AA, Arceci RJ, Katzenstein HM, Harbison C, Zhou X, Lu H, Langer C, Weber M, Gore L. Journal of Clinical Oncology. 27:5102-8, 2009.
- Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Gao S, Mobley A, Miller C, Boklan J, Chandra J. Leukemia Research. 32:771-80, 2008.
- Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM. Clinical Cancer Research. 13:1783-8, 2007.
- Little patients, losing patience: pediatric cancer drug development. Boklan J. Molecular Cancer Therapeutics. 5:1905-8, 2006.
- Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. Boklan J, Nanjangud G, MacKenzie KL, May C, Sadelain M, Moore MA. Cancer Research. 62:2104-14, 2002.
- Lung transplantation after allogeneic marrow transplantation in pediatric patients: the Memorial Sloan-Kettering experience. Heath JA, Kurland G, Spray TL, Kernan NA, Small TN, Brochstein JA, Gillio AP, Boklan J, O'Reilly RJ, Boulad F. Transplantation. 72:1986-90, 2001.